Cardiothoracic & vascular anaesthesia

Volatile Versus Total Intravenous Anesthesia on Postoperative Delirium in Adult Patients Undergoing Cardiac Valve Surgery: A Randomized Clinical Trial

Anesth AnalgPublished Randomised controlled trial

Primary result · Postoperative deliriumResult — go to the resultRelative risk 0.80 95% CI 0.55–1.16

Authors' conclusion

Among patients undergoing on-pump cardiac valve surgery, anesthesia maintenance with a volatile agent did not result in significantly fewer occurrences of postoperative delirium than propofol-based TIVA.

Study context

Population
Adults scheduled for on-pump cardiac valve surgery or combined valve with coronary artery bypass grafting (CABG) surgery, university academic hospital in China, February 2019 to January 2021676 assessed for primary outcome
Participants
684 adults
Comparison
Volatile anaesthesia vs propofol-based total intravenous anesthesia (TIVA) for anaesthesia maintenance
  • Volatile anesthesian = 337
  • Propofol-based TIVAn = 339reference
Primary endpoint
Incidence of delirium (CAM-ICU)
Follow-up
First 7 days after surgery
Methodological detailssingle-centre
  • Single-centre

Primary result

Postoperative delirium

Relative risk

0.80

95% CI 0.55–1.16

P = 0.231

Events by treatment group

Volatile anesthesia vs Propofol-based TIVA
RR 0.80 (95% CI 0.55–1.16); P = 0.231

As reported in the abstract

Secondary outcomes

Duration and subtypes of delirium, 30-day mortality, pain score, major morbidity, duration of mechanical ventilation, intensive care unit (ICU) and hospital LOS

No significant differences between the groups in any secondary outcome

Original publication

Volatile Versus Total Intravenous Anesthesia on Postoperative Delirium in Adult Patients Undergoing Cardiac Valve Surgery: A Randomized Clinical Trial. Anesth Analg. Published 27 October 2022. doi:10.1213/ane.0000000000006257

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.